Experimental drug axatilimab made available for one patient with chronic GVHD
NCT ID NCT05544032
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This program offers expanded access to the drug axatilimab for a single patient with chronic graft versus host disease (GVHD), a complication after a stem cell transplant. The patient receives intravenous doses every two weeks. Approval is needed from the company, an ethics committee, and the FDA.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axatilimab
- What this could lead to
- If it works, this could provide a treatment option for chronic GVHD when other therapies have failed.
- What could go wrong
- This is a single-patient program, not a full clinical trial. Results may not apply to others, and risks like infection or side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VS. HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.